Q&A: New­ly-mint­ed CSL chief ex­ec­u­tive Paul McKen­zie and chief med­ical of­fi­cer Bill Mez­zan­otte

Paul McKen­zie took over as CEO of Aus­tralian phar­ma gi­ant CSL this month, fol­low­ing in the foot­steps of long-time CSL vet Paul Per­reault.

With an eye on mR­NA, and quick­ly com­mer­cial­iz­ing its new, $3.5 mil­lion-per-shot gene ther­a­py for he­mo­phil­ia B, McKen­zie and chief med­ical of­fi­cer Bill Mez­zan­otte an­swered some ques­tions from End­points News this af­ter­noon about where McKen­zie is go­ing to take the com­pa­ny and what ad­vances may be com­ing to mar­ket from CSL’s pipeline. Be­low is a light­ly edit­ed tran­script.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN